Dezhan Healthcare Company Limited (SHE:000813)

Market Cap	7.30B -15.7%
Revenue (ttm)	396.16M -12.8%
Net Income	-357.73M
EPS	-0.17
Shares Out	2.10B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,844,348
Open	3.600
Previous Close	3.350
Day's Range	3.450 - 3.690
52-Week Range	2.750 - 4.930
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Dezhan Healthcare Company

Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China. The company offers atorvastatin calcium tablets, amlodipine-atorvastatin calcium tablets, warfarin sodium tablets, trimetazidine hydrochloride tablets, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, hydroxyurea tablets, colchicine tablet, and oseltamivir phosphate capsules. It also involved in the provision o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1980
• Employees: 1,067
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000813

Financial Performance

In 2025, Dezhan Healthcare Company's revenue was 396.81 million, a decrease of -14.94% compared to the previous year's 466.49 million. Losses were -345.42 million, 1592.2% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 20, 2026

Data Sources Report a data error